Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$112.46 USD

112.46
6,131,334

-2.05 (-1.79%)

Updated Aug 5, 2025 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Gilead (GILD) Up 10.3% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Bryan Hayes headshot

Follow the Leader: 2 Biopharma Stocks Showing Relative Strength in 2025

by Bryan Hayes

Despite a correction to begin the year, there are a few pockets of the market that are working.

Zacks Equity Research

Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.

Ekta Bagri headshot

Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & More

by Ekta Bagri

TSVT and PTGX are in the spotlight this week following an acquisition agreement and study data, respectively.

Zacks Equity Research

GILD Data on Once-Yearly Lenacapavir for HIV Prevention Positive

by Zacks Equity Research

Gilead Sciences' data on two novel, once-yearly formulations of lenacapavir for PrEP support the further development of the drug.

Zacks Equity Research

ARVN Stock Plunges 53% Following Mixed Data From Breast Cancer Study

by Zacks Equity Research

Arvinas stock plummets 53% on mixed data from phase III metastatic breast cancer study on lead pipeline candidate, vepdegestrant.

Zacks Equity Research

The Zacks Analyst Blog Highlights Exelon, Gilead Sciences, Plains All American Pipeline, Sportradar and Cintas

by Zacks Equity Research

Exelon, Gilead Sciences, Plains All American Pipeline, Sportradar and Cintas are part of the Zacks top Analyst Blog

Derek Lewis headshot

These 3 Attractive Stocks Keep Cruising Higher

by Derek Lewis

Despite recent negativity, several stocks, including Verizon Communications, Gilead Sciences, and Alibaba, have shaken off the woes, showing stability and relative strength throughout the period.

Zacks Equity Research

NVO Stock Down 9% as CagriSema Misses Target in Second Obesity Study

by Zacks Equity Research

Novo Nordisk stock slumps as the 15.7% weight loss achieved with its next-gen obesity candidate, CagriSema, in the second phase III study, missing the guidance of 25%.

Zacks Equity Research

KOD Completes Enrollment in Phase III Study for Eye Disease Candidate

by Zacks Equity Research

Kodiak reports completing patient enrollment in its late-stage study evaluating tarcocimab for diabetic retinopathy.

Nalak Das headshot

Buy 5 Non-Tech High-Flying Nasdaq Stocks Amid Index's Recent Bloodbath

by Nalak Das

We have narrowed our search to five Nasdaq Composite-listed non-tech stocks that have provided double-digit returns year to date. These are: EXC, GILD, PAA, SRAD, CTAS.

Sanghamitra Saha headshot

S&P 500 ETF's Worst Week Since September: 5 Top Stocks Poised to Rise

by Sanghamitra Saha

These top-ranked stocks of the S&P 500 index have gained in the index's worst week since September. These stocks have more room to run.

Zacks Equity Research

Zacks Investment Ideas feature highlights: Gilead Sciences and Johnson & Johnson

by Zacks Equity Research

Gilead Sciences and Johnson & Johnson are part of the Zacks Investment Ideas article.

Zacks Equity Research

INCY Opzelura Shows Superior Efficacy in 2 Prurigo Nodularis Studies

by Zacks Equity Research

Incyte reports positive data from two phase III studies evaluating Opzelura for prurigo nodularis in adults.

Zacks Equity Research

EC Approves Bristol Myers' Opdivo Plus Yervoy for First-Line HCC

by Zacks Equity Research

The EC approves BMY's combination of Opdivo and Yervoy for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma.

Zacks Equity Research

Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Gilead Sciences (GILD) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.

Zacks Equity Research

LLY/INCY Olumiant Shows Superior Efficacy in Pediatric Alopecia Study

by Zacks Equity Research

Eli Lilly and INCY announce positive efficacy data from the late-stage alopecia study of baricitinib in adolescent patients.

Shaun Pruitt headshot

Buy Gilead Sciences (GILD) Stock at 52-Week Highs?

by Shaun Pruitt

Medical pioneer Gilead Sciences (GILD) has seen its stock etch out new 52-week highs as the broader market pulled back sharply in recent weeks.

Zacks Equity Research

Krystal Biotech Rises 15.8% in a Month: Should You Buy Now or Wait?

by Zacks Equity Research

KRYS stock surges 15% in a month on strong uptake of Vyjuvek and encouraging pipeline progress. We are optimistic about the stock as we believe there is room for further growth.

Kaibalya Pravo Dey headshot

3 Healthcare Stocks With Strong EPS Growth Potential to Buy in 2025

by Kaibalya Pravo Dey

GILD, OPCH and AVAH demonstrate resilience with impressive earnings surprise history.

Zacks Equity Research

Is Pacer US Cash Cows 100 ETF (COWZ) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for COWZ

Zacks Equity Research

Editas Q4 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down

by Zacks Equity Research

EDIT stock is down following the announcement of dismal fourth-quarter 2024 results as both earnings and revenues miss estimates.

Zacks Equity Research

FATE Q4 Earnings Beat, Autoimmunity, Oncology Programs in Focus

by Zacks Equity Research

FATE Therapeutics' Q4 loss and revenues improve year over year. Its innovative pipeline is in focus.

Zacks Equity Research

Should Pacer US Cash Cows 100 ETF (COWZ) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for COWZ

Zacks Equity Research

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.